Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.
about
Mechanisms of drug resistance in colon cancer and its therapeutic strategiesDevelopment, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1The reversal of antineoplastic drug resistance in cancer cells by β-elemeneGlycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cellsbba, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10)Changes in the expression of miR-381 and miR-495 are inversely associated with the expression of the MDR1 gene and development of multi-drug resistanceGalectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via β-catenin/GSK-3β modulation in colorectal carcinomaImatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapyTTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transportersHIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein.Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy.Inhibition of breast cancer resistance protein (ABCG2) in human myeloid dendritic cells induces potent tolerogenic functions during LPS stimulationmicroRNA 490-3P enhances the drug-resistance of human ovarian cancer cellsRaltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.Roles of sildenafil in enhancing drug sensitivity in cancer.Eradication of Human Ovarian Cancer Cells by Transgenic Expression of Recombinant DNASE1, DNASE1L3, DNASE2, and DFFB Controlled by EGFR Promoter: Novel Strategy for Targeted Therapy of Cancer.Plasma metabolite profiling and chemometric analyses of lung cancer along with three controls through gas chromatography-mass spectrometry.Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cellsSalinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR human breast cancer cells via decreased efflux of doxorubicin.Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy.Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs.PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporterA composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy.A potential daidzein derivative enhances cytotoxicity of epirubicin on human colon adenocarcinoma Caco-2 cellsThe chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells.N-alkylated isatins evade P-gp mediated efflux and retain potency in MDR cancer cell linesTargeting the autophagy pathway using ectopic expression of Beclin 1 in combination with rapamycin in drug-resistant v-Ha-ras-transformed NIH 3T3 cells.Epigenetics in cancer stem cells.Effects of curcumin on ion channels and transporters.Lack of ABCG2 Leads to Biventricular Dysfunction and Remodeling in Response to HypoxiaCancer Stem Cells: A Moving TargetMultidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines?Nanodrug delivery in reversing multidrug resistance in cancer cells.Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach.Understanding the colon cancer stem cells and perspectives on treatment.Preparation and characterization of stable nanoliposomal formulation of fluoxetine as a potential adjuvant therapy for drug-resistant tumors.Inhibition of paclitaxel resistance and apoptosis induction by cucurbitacin B in ovarian carcinoma cells.The regulation of human hepatic drug transporter expression by activation of xenobiotic-sensing nuclear receptors.
P2860
Q26738528-72951B94-014A-4733-A94C-A8C03336CD9DQ26778957-C2B791EA-51BD-4E07-A338-00F4BCBAFFD3Q26787004-6BE5C885-5700-4D04-A82B-6D6F99D1F771Q28477764-1766A6D5-EB4D-4EA1-8EFC-AA3C6A873A78Q28533538-33F917F3-1E47-43FC-9B8D-3073F76E9CD9Q28535423-EC671AEA-24F9-4A1F-81B4-D580F1F5963AQ28535429-BD7F55DB-0929-4104-9D6D-111880869FAFQ33511437-6909298E-0582-4326-B04F-0B765346CF7EQ33578222-19399ED8-BAC0-422A-BBBE-73B68B3DE850Q33584376-EDC392AC-6D30-457A-9F2C-3D1F9F80F0F2Q33717131-3F606D4A-A041-4615-AA7E-45E02B4D043EQ33814552-251FA2CE-4139-4587-BC2D-9FC00F069738Q34027988-C844B7DF-FAD6-4721-8C49-EED79174EF74Q34150950-1F25908A-CC73-4ECF-B1E6-2093E2E748A6Q34993146-D2126769-14A8-4EBE-86EB-7EABF48FD9DBQ35022148-7FA706F7-31B8-4A1A-B8C6-8CA332E269F1Q35109273-404AD57A-789B-48A3-9731-4EAB15A43119Q35119518-A2C38E54-BC1A-43E8-9CA6-B98895AE9672Q35312427-FEE0B987-0D0F-4BBE-B098-F324F2AA5C57Q35609552-DD7FD6C1-929F-4236-82FA-B2F42B482ADDQ35915497-E6B937D9-7EA9-4B14-A805-614CCC6277DDQ36027132-2F06C4F1-382B-483C-845E-9DF88F8FFDF0Q36124056-203747E7-9C2E-489F-9827-CC6C10EBC34CQ36234061-B5069052-4B5C-4DA3-AA16-1C50DDC50993Q36589869-C8C5D034-8147-495E-8114-950E337A52C0Q37065525-FE829766-BED6-4B3B-83D1-29F78655473CQ37096409-26713E7C-1B41-4EEA-B51E-29BC3955456CQ37599431-EC79B035-A6C5-49DD-AC22-C4E22D75B626Q37618640-55C792CE-670A-47B7-A53A-357A24BB2A00Q37629713-6AFF7C5A-D481-47F9-903A-6AA0DDF77039Q37653867-E179142F-926C-4E59-85B2-EB77ADBBE12CQ38126498-F7A9FBBA-10A0-4761-B752-6F76050F2804Q38144200-61734EF1-9C0D-4ED7-BEA0-C06FE8E344C1Q38234908-5C1E230D-F3B8-4E2C-B924-D7B05723304CQ38246305-CF6A296F-5595-4D63-93FD-44F6EDC4A854Q38324456-EA5A98DD-C4DF-47E8-999A-54D440005A2CQ38356774-85D8FFB9-FD48-4F85-B2FC-171AFDEFF01FQ38627806-6B5F0421-22F6-498D-99C4-C6C64C52D51AQ38697712-11EBEE79-0020-4183-8AEE-4CCD72D5C328Q38750759-7724C895-A22F-4325-A4A0-3F0ABC23CA63
P2860
Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reversal of ABC drug transport ...... luation of current strategies.
@en
Reversal of ABC drug transport ...... luation of current strategies.
@nl
type
label
Reversal of ABC drug transport ...... luation of current strategies.
@en
Reversal of ABC drug transport ...... luation of current strategies.
@nl
prefLabel
Reversal of ABC drug transport ...... luation of current strategies.
@en
Reversal of ABC drug transport ...... luation of current strategies.
@nl
P2093
P2860
P1476
Reversal of ABC drug transport ...... luation of current strategies.
@en
P2093
Anna Maria Calcagno
Chung-Pu Wu
Suresh V Ambudkar
P2860
P304
P356
10.2174/1874467210801020093
P577
2008-06-01T00:00:00Z